Marinus Pharmaceuticals (MRNS) Cut to Hold at BidaskClub
BidaskClub lowered shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a buy rating to a hold rating in a research report sent to investors on Thursday.
Several other analysts also recently weighed in on the company. JMP Securities reaffirmed an outperform rating and set a $11.00 target price (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 12th. ValuEngine raised Marinus Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, August 11th.
Shares of Marinus Pharmaceuticals (NASDAQ MRNS) traded down $0.78 during trading on Thursday, reaching $7.86. The company’s stock had a trading volume of 4,045,517 shares, compared to its average volume of 1,385,721. Marinus Pharmaceuticals has a 52-week low of $0.82 and a 52-week high of $8.90.
Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.02.
Hedge funds have recently modified their holdings of the company. Jennison Associates LLC increased its position in shares of Marinus Pharmaceuticals by 108.1% during the 2nd quarter. Jennison Associates LLC now owns 811,665 shares of the biopharmaceutical company’s stock valued at $1,112,000 after purchasing an additional 421,600 shares during the period. EAM Investors LLC acquired a new position in shares of Marinus Pharmaceuticals during the 3rd quarter valued at $554,000. Granite Point Capital Management L.P. increased its position in shares of Marinus Pharmaceuticals by 250.3% during the 3rd quarter. Granite Point Capital Management L.P. now owns 2,684,848 shares of the biopharmaceutical company’s stock valued at $15,760,000 after purchasing an additional 1,918,400 shares during the period. KCG Holdings Inc. increased its position in shares of Marinus Pharmaceuticals by 29.5% during the 1st quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 14,692 shares during the period. Finally, Perceptive Advisors LLC acquired a new position in shares of Marinus Pharmaceuticals during the 3rd quarter valued at $8,527,000. Institutional investors own 49.77% of the company’s stock.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.